Epizyme

Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors.   Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Epizyme (EPZM) posts a wider-than-expected loss for the first quarter. Revenues also miss estimates.

Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates

Epizyme, Inc. (NASDAQ:EPZM ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Grant Bogle – President and Chief Executive Officer Shefali Agarwal - Senior Medical Adviser, Interim Chief Medical and Development Officer Joe Beaulieu - Senior Vice President, Head of Finance Jerald Korn - Chief Operating Officer Conference Call Participants Peter Lawson - Barclays Peyton Bohnsack - Cowen Operator Hello, and welcome to Epizyme's First Quarter 2022 Financial Results Conference Call. At this time, all participants on a listen-only mode.

Epizyme, Inc. (EPZM) CEO Grant Bogle on Q1 2022 Results - Earnings Call Transcript

Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported first quarter 2022 financial results and provided a business update. “The relapsed or refractory follicular lymphoma treatment landscape is rapidly changing, and we believe TAZVERIK® is poised to grow at an accelerated rate as the year progresses. We saw en

Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update

Bausch Health Companies Inc

Catalyst Pharmaceuticals

Exelixis

Reata Pharmaceuticals

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

Epizyme (EPZM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Epizyme (EPZM) Upgraded to Buy: What Does It Mean for the Stock?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference call to discuss its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 3

Epizyme Announces Date of First Quarter 2022 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that the Company has granted equity awards to Jerald Korn, the Company's Chief Operating Officer, with a grant date of April 1, 2022, as equity inducement awards outside of the Company's 2013 Stock Incentive Plan and material to Mr. Korn's acceptance of em

Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

Why Is Epizyme (EPZM) Down 29.7% Since Last Earnings Report?

Epizyme's (EPZM) lead drug, Tazverik, is approved to treat follicular lymphoma and epithelioid sarcoma in the United States. Stiff competition in the target remains an overhang.

Epizyme (EPZM) Down More Than 50% in Past 3 Months: Here's Why

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced a clinical update as well as the appointment of Jerald Korn as Chief Operating Officer, reporting to President and Chief Executive Officer, Grant Bogle. “We are excited to welcome Jerald to Epizyme at a pivotal time for the organization,” said Mr. Bogle. “

Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update

Epizyme (EPZM) posts a wider-than-expected loss for the fourth quarter. Revenues also miss estimates.

Epizyme (EPZM) Q4 Loss Wider Than Expected, Revenues Lag

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today announced its participation in two investor conferences in March. Cowen 42nd Annual Health Care Conference Shefali Agarwal, Chief Medical Officer, will participate in the Cowen 42nd Annual Health Care Conference as part of the Targeted Oncology panel. Tuesday, March 8, at 9:10am EST B

Epizyme to Participate in Upcoming Healthcare Conferences in March

Epizyme's (EPZM) CEO Grant Bogle on Q4 2021 Results - Earnings Call Transcript

Epizyme (EPZM) delivered earnings and revenue surprises of -19.51% and 50.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) Reports Q4 Loss, Misses Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer against novel epigenetic targets, today reported fourth quarter and full year 2021 financial results and provided business and portfolio updates. “Epizyme entered 2022 demonstrating continued progress on our commercial efforts to drive prescription growth for TAZVERIK as a monotherapy, as well as advancing our key

Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide a business update on Tuesday, March 1, 2022 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer t

Epizyme Announces Date of Fourth Quarter and Full Year 2021 Financial Results

Epizyme (EPZM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Epizyme (EPZM) This Earnings Season?

Epizyme (EPZM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Epizyme (EPZM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

The small biopharmaceutical company bounced back after its shares lost half their value the week before.

Why Shares of Epizyme Soared 32.1% This Week

Inspira Technologies Oxy BHN Ltd

Senseonics Holdings

Here are three penny stocks to check out today The post 3 Hot Penny Stocks to Watch Under $4 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks to Watch Under $4 Right Now

Pixelworks

Accelerate Diagnostics

The Euro surged to $1.13 against the US dollar this morning after recent data showed the Eurozone inflation increased to a new record high of 5.1% in January. Investors, meanwhile, focused on some notable insider trades.

Insiders Buying Pixelworks And 4 Other Penny Stocks

The heavy selling pressure might have exhausted for Epizyme (EPZM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 54.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Epizyme (EPZM)

Epizyme (EPZM) to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.

Epizyme (EPZM) Stock Dives on Public Offering of Common Stock

News of a dilutive share issue left investors feeling queasy.

News for Epizyme Stock (EPZM)